A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
NCT02042378
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
19
Enrollment
INDUSTRY
Sponsor class
Conditions
Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG:
Rucaparib
Sponsor
pharmaand GmbH